Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Short Interest Rises 160.1%

Posted by Brenda Bartman on Oct 14th, 2026

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report) saw a large growth in short interest in September. As of September 30th, there was short interest totaling 11,552 shares, a growth of 160.1% from the September 15th total of 4,442 shares. Approximately 2.6% of the shares of the stock are sold short. Based on an average daily volume of 83,653 shares, the short-interest ratio is currently 0.1 days.

Cyclerion Therapeutics Stock Performance

KRSA traded up $2.66 during trading on Wednesday, reaching $34.32. 193,564 shares of the stock were exchanged, compared to its average volume of 288,718. The company has a market cap of $22.96 million, a price-to-earnings ratio of -2.95 and a beta of 1.72. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36.

Institutional Investors Weigh In On Cyclerion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC acquired a new stake in Cyclerion Therapeutics in the 2nd quarter valued at about $1,013,000. Braidwell LP acquired a new position in Cyclerion Therapeutics during the second quarter worth about $532,000. Finally, BlackRock Inc. acquired a new position in Cyclerion Therapeutics during the second quarter worth about $57,000. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KRSA. Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a report on Wednesday, September 9th. Guggenheim began coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 28th. They issued a “buy” rating and a $70.00 price objective for the company. Wall Street Zen raised shares of Cyclerion Therapeutics to a “sell” rating in a report on Saturday, October 3rd. Wedbush initiated coverage on shares of Cyclerion Therapeutics in a report on Monday, October 5th. They set an “outperform” rating and a $44.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.00.

Read Our Latest Stock Report on Cyclerion Therapeutics

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease.